| Literature DB >> 33728290 |
Jin Long1, Chung Lyul Lee1, Seung Woo Yang1, Ji Yong Lee1, Jae Geun Lee1, Ki Hak Song1, Jae Sung Lim1, Jong Mok Park1, Yong Gil Na1, Geon Gil2, Ju Hyun Shin1.
Abstract
We studied the long-term efficacy and safety of cystocele operation by polypropylene mesh. A total of 198 women with stage ≥2 cystocele who had anterior vaginal wall repair with transobturator four-arm polypropylene mesh during 2003 to 2015 were evaluated. Outcomes including clinical characteristics and complications were reviewed by extracting patient data from electronic medical records. In addition, telephone interviews were conducted using a validated questionnaire along with physical examination. The follow-up period was 9.3±0.3 years. The cystocele stage in patients was significantly decreased post-operation compared to that preoperation. The anatomical cure rate for cystocele was 93.4%, and that for stress urinary incontinence was 95%. Comparing the three questionnaires indicated overall average score was improved significantly, except for Female Sexual Function Index Assessment. Early complications were either resolved spontaneously or controlled medically in four cases of hematoma or abscess, three cases of vaginal infection and urinary tract infection, and four cases of difficult micturition. In late complications, four cases of pain were managed, five cases of recurrence were observed and two cases of mesh exposure were treated with ointment and local excision. Transobturator four-arms mesh is an effective and safe method for cystocele repair with low rate of recurrence and complications. We suggest that the use of transobturator four-arm mesh is a still good choice for the old patients with cystocele who are not suitable for general anesthesia and reside in areas where laparoscopy and robots are not available.Entities:
Keywords: Cystocele; Long-term follow-up; Surgical mesh
Year: 2021 PMID: 33728290 PMCID: PMC7939986 DOI: 10.12965/jer.2142098.049
Source DB: PubMed Journal: J Exerc Rehabil ISSN: 2288-176X
Characteristics of the study population (n=198)
| Characteristic | Value |
|---|---|
| Age (yr) | 61.7±0.8 |
|
| |
| Follow-up time (yr) | 9.3±0.3 (0.6–18) |
|
| |
| Body mass index (kg/m2) | 25.5±0.2 (16.3–38.3) |
|
| |
| Smoking | 5 (2.5) |
|
| |
| Diabetes mellitus | 22 (11.1) |
|
| |
| Hypertension | 71 (35.9) |
|
| |
| Cardiovascular diseases | 11 (5.6) |
|
| |
| Menopause | 21 (10.6) |
| No | 21 (10.6) |
| Yes | 177 (89.4) |
|
| |
| NSVD | 3.0±0.1 (0–7) |
|
| |
| Caesarean section | 5 (2.5) |
|
| |
| Hysterectomy | 4 (2.0) |
|
| |
| Repair of rectocele | 125 (63.1) |
|
| |
| 1H pad test (g) | 17.0±1.9 (0–80) |
Values are presented as mean±standard error of the mean (range) or number (%).
NSVD, normal vaginal deliver.
Assessments using questionnaire forms and urodynamics (UDS)
| Questionnaire | Preoperative | Postoperative | |
|---|---|---|---|
| ICIQ (total score) | 15.5±0.2 | 1.7±0.4 | <0.01 |
| Slight | 0 (0) | 87 (82.1) | |
| Moderate | 27 (25.0) | 12 (11.3) | |
| Severe | 58 (55.0) | 5 (4.7) | |
| Very severe | 21 (20.0) | 0 (0) | |
|
| |||
| KHQ (total score) | 69.6±1.1 | 17.1±2.1 | <0.01 |
| General health perception | 3.7±0.1 | 1.4±0.1 | |
| Incontinence impact score | 2.7±0.1 | 1.2±0.1 | |
| Role limitations | 5.5±0.2 | 2.5±0.1 | |
| Physical limitations | 5.4±0.2 | 2.5±0.1 | |
|
| |||
| PPBC (total score) | 3.7±0.1 | 0.8±0.1 | <0.01 |
|
| |||
| FSFI (total score) | 24.7±2.3 | 21.5±0.9 | >0.05 |
|
| |||
| UDS, mean±SD | |||
| MUCP (cmH2O) | 48.1±22.0 | - | - |
| Pdet Qmax (cmH2O) | 6.9±8..6 | - | - |
| Pdet max flow (mL/sec) | 13.9±14.8 | - | - |
| Voding time (sec) | 50.5±38.4 | 46.9±45.8 | >0.05 |
| Voding volume (mL) | 300.5±162.6 | 268.9±143.7 | >0.05 |
| Residual urine volume (mL) | 61.3±90.8 | 57.7±94.61 | >0.05 |
Values are presented as mean±standard error of the mean or number (%) unless otherwise indicated.
ICIQ, Incontinence Questionnaire; KHQ, King’s Health Questionnaire; PPBC, patient perception of bladder condition; FSFI, Female Sexual Function Index assessment; SD, standard devation; MUCP, maximum urethra closure pressure; Pdet Qmax, detrusor pressure at maximal urinary flow rate.
Stages of POP-Q system and SUI in patients before and after surgery
| Variable | Preoperative | Postoperative | |
|---|---|---|---|
| POP-Q | n=198 | n=152 | <0.01 |
| Cystocele stage 0 | 0 (0) | 130 (85.5) | |
| Cystocele stage I | 0 (0) | 13 (8.6) | |
| Cystocele stage II | 53 (26.8) | 7 (4.6) | |
| Cystocele stage III | 135 (68.2) | 1 (0.5) | |
| Cystocele stage IV | 10 (5.1) | 1 (0.5) | |
|
| |||
| SUI grade | n=105 | n=152 | <0.01 |
| Grade 0 | 26 (24.8) | 134 (88.2) | |
| Grade I | 18 (17.0) | 13 (12.3) | |
| Grade II | 17 (16.0) | 2 (2.0) | |
| Grade III | 44 (41.5) | 3 (3.0) | |
Values are presented number (%).
POP-Q, Pelvic Organ Prolapse Quantification; SUI, stress urinary incontinence.
Scale of the early and late postoperative complications
| Complication | Value |
|---|---|
| Early (mo) | 2.0±0.8 |
|
| |
| Hematoma or abscess | 4 (2.0) |
| Spontaneous regression | 3 (1.5) |
| Treatment | 1 (0.9) |
|
| |
| Urinary retention | 0 (0) |
|
| |
| Difficult micturition | 4 (2.0) |
|
| |
| Vaginal infection | 3 (1.5) |
|
| |
| Urinary tract infection | 3 (1.5) |
|
| |
| Denovo urgency | 16 (8) |
| Disappear spontaneously | 10 (5.0) |
| Received medication | 6 (0.3) |
|
| |
| Late (yr) | 9.1±0.3 |
|
| |
| Pain location | 4 (3.6) |
| Thigh pain | 1 (0.9) |
| Vaginal pain | 1 (0.9) |
| Nonvaginal pelvic pain | 2 (1.8) |
|
| |
| Difficult micturition | 4 (2.0) |
|
| |
| Mesh exposure | 2 (1.9) |
| Topic treatment | 1 (0.9) |
| Repeat for mesh exposure | 1 (0.9) |
|
| |
| Recrudescence | 5 (4.7) |
|
| |
| Other | 1 (0.9) |
Values are presented number (%).
Other: vaginal bleeding.